Multihance (Gadobenate Dimeglumine)

Multihance is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging of several organ systems.

• Brain and spinal cord MRI: provides enhanced visualization of lesions, tumors, and vascular structures.
• Liver MRI: improves detection and characterization of focal liver lesions.
• Cardiovascular MRI: enables detailed assessment of cardiac anatomy, function, and perfusion.
• MR angiography: highlights arterial and venous vessels for precise vascular mapping.

• Gadobenate dimeglumine is a paramagnetic gadolinium chelate that shortens the T1 relaxation time of nearby water protons. After intravenous injection it distributes into the extracellular fluid and transiently accumulates in tissues with increased vascularity or disrupted blood‑brain barrier. The resulting T1 shortening increases signal intensity on T1‑weighted MRI sequences, allowing clearer delineation of anatomy and pathology.

Adverse reactions to Multihance are generally infrequent but may occur following intravenous administration.

Common Side Effects

• Nausea: mild, transient feeling of stomach upset.
• Headache: temporary discomfort often resolving without intervention.
• Injection site discomfort: mild pain or burning at the infusion site.
• Warm sensation: brief feeling of warmth or flushing.

Serious or Rare Side Effects

• Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment.
• Severe allergic reaction: anaphylaxis or hypersensitivity requiring immediate medical attention.
• Cardiac arrhythmia: uncommon rhythm disturbances observed during or after injection.
• Gadolinium retention: long‑term deposition in tissues, potentially leading to unknown effects.

When using Multihance, several precautions should be observed to ensure patient safety and product integrity.

• Renal function assessment: evaluate glomerular filtration rate before administration in patients with kidney disease.
• Pregnancy and lactation: use only if clearly needed, as safety data are limited.
• Prior contrast reactions: review history of allergic reactions to gadolinium agents.
• Concomitant medications: consider potential for increased risk of NSF with certain chelating agents.
• Patient monitoring: observe for immediate hypersensitivity signs during and after injection.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other substances that affect gadolinium handling or patient safety.

Major Interactions (Avoid)

• Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid or use alternative agents.
• Iron chelators (e.g., deferoxamine): can compete for gadolinium binding, reducing efficacy.
• High-dose calcium supplements: may alter gadolinium distribution.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask symptoms of hypersensitivity reactions.
• Antihistamines: may reduce effectiveness of pre‑medication protocols.
• Diuretics: affect renal clearance, requiring closer monitoring of kidney function.